Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

OK432 (Picibanil) in the Treatment of Lymphatic Malformations

NCT03427619
View directory record Official record
Conditions
Lymphatic Malformations
Interventions
OK432
Drug
Lead sponsor
Richard JH Smith
Other
Eligibility
6 Months to 17 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
14
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial

NCT05650645
View directory record Official record
Conditions
Tinnitus
Interventions
incobotulinum toxin A, Placebo-Saline
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

NCT04597372
View directory record Official record
Conditions
Urinary Retention Postoperative
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older · Female only
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 21, 2026, 1:51 AM EDT
Terminated Phase 3 Interventional Results available

Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

NCT00926575
View directory record Official record
Conditions
Acute Gastrointestinal Graft vs Host Disease
Interventions
oral beclomethasone 17,21-dipropionate, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Buffalo, New York • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

NCT01286012
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Soluble Ferric Pyrophosphate in liquid bicarbonate, Placebo: Conventional liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Tempe, Arizona • Granada Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

NCT00952081
View directory record Official record
Conditions
Hypertension, Brain Tumor, Epilepsy
Interventions
Clevidipine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 21, 2026, 1:51 AM EDT
Withdrawn No phase listed Observational

RELISTOR's Effects on Opioid-Induced Constipation

NCT04930237
View directory record Official record
Conditions
OIC
Interventions
Relistor Injectable Product, Docusate Calcium, Bisacodyl, Milk of magnesia, Magnesium citrate, Senna, Enema
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

NCT01728077
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

NCT00135577
View directory record Official record
Conditions
Cancer, Bowel Dysfunction
Interventions
alvimopan, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
14
States / cities
Duarte, California • Fountain Valley, California • La Verne, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

NCT02725957
View directory record Official record
Conditions
Healthy Volunteer Subjects
Interventions
Trehalose for IV Infusion, Saline 0.9% IV
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

NCT01023581
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

NCT02197130
View directory record Official record
Conditions
Huntington's Disease
Interventions
PF-02545920, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

NCT04681066
View directory record Official record
Conditions
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
Interventions
CM-4620 Injectable Emulsion or CM-4620-IE, Placebo
Drug · Other
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

NCT04690556
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab)
Drug
Lead sponsor
Lupin Ltd.
Industry
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Beverly Hills, California • Delray Beach, Florida • Hagerstown, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 21, 2026, 1:51 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Acetazolamide Efficacy in Ataxia in PMM2-CDG

NCT04679389
View directory record Official record
Conditions
Pmm2-CDG, CDG1A
Interventions
Placebo, Acetazolamide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
4 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

NCT02500121
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Placebo, Pembrolizumab
Other · Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 21, 2026, 1:51 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users

NCT07813026
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Oxycodone 20mg, gabapentin 600 mg, Gabapentin 1200mg, Gabapentin 600 mg + Oxycodone 20 mg, Gabapentin 1200 mg + Oxycodone 20 mg
Drug
Lead sponsor
Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 1:51 AM EDT
Terminated Phase 1 Interventional

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

NCT03658135
View directory record Official record
Conditions
Primary Tauopathies, Corticobasal Degeneration Syndrome, Frontotemporal Lobar Degeneration With Tau Inclusions, MAPT Mutation Carriers, Symptomatic, Traumatic Encephalopathy Syndrome, Nonfluent Aphasia, Progressive
Interventions
BIIB092, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 21, 2026, 1:51 AM EDT
Withdrawn Phase 1 Interventional

IVIG in Acute Ischemic Stroke: A Pilot Study

NCT01628055
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Privigen, Normal Saline
Biological · Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
45 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate Efficacy and Tolerability of a Cosmetic Product for Arm Firming

NCT04065035
View directory record Official record
Conditions
Photodamaged Skin, Skin Care
Interventions
Topical Body Firming Moisturizer, Body Cleanser, Sunscreen, Placebo Moisturizer
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
40 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 21, 2026, 1:51 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

NCT03278808
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 21, 2026, 1:51 AM EDT
Terminated Not applicable Interventional

Study of Probable Benefit of the Neuro-Spinal Scaffold™ in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care

NCT03762655
View directory record Official record
Conditions
Injury, Spinal Cord
Interventions
Neuro-Spinal Scaffold
Device
Lead sponsor
InVivo Therapeutics
Industry
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Sacramento, California • San Diego, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 21, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

NCT00465517
View directory record Official record
Conditions
Partial Epilepsy, Catamenial Epilepsy
Interventions
Ganaxolone, Placebo
Drug · Other
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 21, 2026, 1:51 AM EDT